Journalists

Media & Press relations

Our latest press releases

September 05, 2024

First-Half 2024 Results

Marcy l’Etoile (France), September 5th, 2024 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4th under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2024.

Discover more

Swipe for more

June 26, 2024

bioMérieux receives U.S. FDA Special 510(k) clearance and CLIA-waiver for its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini

bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel Mini has received U.S. Food and Drug Administration (FDA) Special 510(k) clearance and CLIA-waiver (Clinical Laboratory Improvement Amendments).

Read more
June 21, 2024

bioMérieux receives US FDA 510(k) clearance for its AST System VITEK® REVEAL™

bioMérieux, a world leader in in vitro diagnostics, today announces that its VITEK® REVEAL™ AST System, reporting results directly from positive blood cultures, has received U.S. Food and Drug Administration (FDA) 510(k) clearance.

Read more
May 28, 2024

bioMérieux receives FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), an innovative test to improve the assessment of patients with mild traumatic brain injury

bioMérieux, a world leader in the field of in vitro diagnostics, announces the U.S. FDA 510(k) clearance of VIDAS® TBI (GFAP, UCH-L1), a serum-based test to support the assessment of patients with mild traumatic brain injury (mTBI), including concussion.

Read more